IMVT - Immunovant Inc Revenue Breakdown
This article provides a detailed financial overview of Immunovant Inc. (IMVT), covering key metrics such as market cap, income, sales, stock performance, and analyst recommendations. It highlights the company's valuation ratios, insider and institutional ownership, and profitability margins. The data suggests Immunovant is a biotechnology company with no current sales but significant institutional interest.
Chief Technology Officer Of Immunovant Sold 53% Of Their Shares
Immunovant Inc.'s Chief Technology Officer, Jay Stout, recently sold US$1.5 million worth of stock, representing 53% of his holding. While insider selling at the current price isn't as concerning as selling at a lower price, there has been no insider buying in the last year. Insider ownership is 0.8%, prompting caution for potential investors.
IMVT - Immunovant Inc Options
This page provides a detailed financial overview of Immunovant Inc (IMVT), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It also lists key statistics such as EPS, insider and institutional ownership, profitability metrics, and analyst recommendations. The data highlights the company's strong recent performance with significant gains over multiple periods, despite negative income and sales figures.
Chief Technology Officer Of Immunovant Sold 53% Of Their Shares
Immunovant's Chief Technology Officer, Jay Stout, recently sold US$1.5m worth of company stock at US$38.31 per share, representing 53% of his total holding. While the sale occurred near the current stock price, which lessens concern, the significant percentage of shares sold and complete absence of insider buying over the last year raise caution. Insider ownership in Immunovant is 0.8%, indicating some alignment but making careful consideration necessary before investing.
Citi Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $61
Citi has reiterated its Buy rating for Immunovant (IMVT.US) and increased the target price to $61. This indicates a continued positive outlook from Citi on the company's stock performance.
Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing
An insider at Immunovant recently sold shares valued at $1,532,309, as disclosed in a recent SEC filing. This transaction could be of interest to investors tracking insider activity within the company. Further details would typically be available in the full SEC document.
Immunovant CTO Jay Stout sells $1.53m in company stock
Immunovant CTO Jay Stout sold 40,000 shares of the company’s common stock for over $1.53 million on June 26, 2026. This sale occurred while Immunovant shares were trading near their 52-week high, with InvestingPro analysis suggesting the stock is overvalued. Despite this insider sale, Immunovant has recently received multiple analyst upgrades and positive financial projections following promising clinical trial results and a strong product pipeline.
Immunovant (IMVT) CTO Jay S. Stout sells 40,000 shares in open-market trades
Immunovant, Inc. CTO Jay S. Stout reported selling a total of 40,000 shares of the company's common stock in two open-market transactions on June 26, 2026. The shares were sold at weighted average prices of $38.18 and $38.94 per share, totaling approximately $1.53 million. Following these sales, Stout directly holds 218,408 shares of common stock.
Insider Sell: Melanie Gloria Sells 17,714 Shares of Immunovant I
Melanie Gloria, Chief Operating Officer at a subsidiary of Immunovant Inc (IMVT), sold 17,714 shares of the company on June 26, 2026. Following this transaction, Gloria now owns 224,393 shares. Immunovant Inc is a clinical-stage biopharmaceutical company, and this sale marks part of a trend of 33 insider sells against 1 insider buy over the past year.
Price to book forward of Immunovant, Inc. – NASDAQ:IMVT
This article from TradingView focuses on the "Price to book forward" financial metric for Immunovant, Inc. (NASDAQ: IMVT). It is primarily a data page, displaying the period, value, and change for this specific financial indicator related to the biotechnology company. The content itself provides little textual analysis, serving more as a data point for financial market participants.
Immunovant chief legal officer sells $682,886 in stock
Christopher Van Tuyl, Chief Legal Officer at Immunovant, Inc. (NASDAQ:IMVT), sold 17,824 shares of company stock for $682,886 on June 26, 2026, after exercising stock options. The sales occurred while the stock was near its 52-week high, following a significant 137% gain over the past year, and coincided with analysts raising price targets due to promising clinical trials and sales outlooks for Immunovant's drug IMVT-1402. InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value.
Immunovant CFO Tiago Girao sells $384,600 in company stock
Immunovant (NASDAQ:IMVT) CFO Tiago Girao sold 10,000 shares of company stock for approximately $384,600 after exercising stock options for the same number of shares. The sale occurred while Immunovant shares were trading near their 52-week high, having delivered a 137% return over the past year. This transaction follows positive analyst updates and promising clinical trial results for the company.
Immunovant (IMVT) Chief Legal Officer sells 17,824 shares after option exercise
Immunovant, Inc.'s Chief Legal Officer, Christopher Van Tuyl, exercised options for 17,824 shares at $15.20 each and subsequently sold all these shares in open-market transactions for approximately $38.19 to $38.96 per share. Following these transactions, Van Tuyl directly holds 180,597 common shares and 53,707 stock options. This insider trading activity was reported in a Form 4 filing and is considered neutral in its impact and sentiment.
Immunovant (IMVT) CFO exercises options, sells 10,000 shares at ~$38 average
Immunovant, Inc.'s CFO Tiago Girao exercised stock options to acquire 10,000 shares at $15.90 per share and subsequently sold all 10,000 shares in the open market at a weighted average price of $38.46 per share. Following these transactions, Girao holds 247,596 shares of Common Stock. The sale was executed in multiple trades within a price range of $38.00 to $38.90.
Immunovant (IMVT) director sells 1,500 shares after option exercise
Immunovant, Inc. director Atul Pande exercised 1,500 stock options at $8.43 per share and subsequently sold 1,500 common shares at an average price of $38.01. This transaction was part of a pre-planned Rule 10b5-1 plan adopted in December 2025. Following these transactions, Pande directly holds 116,731 common shares, 20,000 indirectly, and retains 68,181 stock options.
IMVT (NASDAQ) Form 144 lists multiple vested restricted stock blocks, 40,000 header
Immunovant, Inc. (IMVT) filed a Form 144 noticing potential sales of common stock under Rule 144, detailing multiple blocks of restricted stock vesting under a registered plan. The filing includes a figure of 40,000 near the securities header and lists various vesting dates in 2024 and 2026 with specific share quantities, such as 17,761 and 5,290. Morgan Stanley Smith Barney LLC Executive Financial Services is named as the broker.
IMVT (NASDAQ: IMVT) files Form 144 for 17,824-share sale after option exercise
Immunovant, Inc. (NASDAQ: IMVT) has filed a Form 144 indicating a planned sale of 17,824 shares on June 26, 2026, stemming from an option exercise under a registered plan, with the transaction to be settled in cash. The filing also disclosed two prior sales by the same entity: 2,634 shares on June 18, 2026, for $93,217.26, and 5,165 shares on April 8, 2026, for $128,246.95. The Securities Compliance Analyst from Rhea-AI views this as a neutral, routine reporting event.
[144] Immunovant, Inc. SEC Filing
This article details an SEC Form 144 filing by Immunovant, Inc. (IMVT) concerning a proposed sale of securities. The filing indicates a sale of 10,000 shares of common stock with an aggregate market value of $384,640.00, acquired through the exercise of options on June 26, 2026.
[144] Immunovant, Inc. SEC Filing
Immunovant, Inc. (IMVT) has filed a Rule 144 notice for the proposed sale of 17,714 shares of common stock, valued at $678,552.48, resulting from three restricted stock vesting events in early 2026. Morgan Stanley Smith Barney LLC is named as the broker. This filing permits holders to sell restricted shares under Rule 144 conditions, with details of actual sales to follow in future reports.
Enterprise value to EBITDA forward of Immunovant, Inc. – NASDAQ:IMVT
This article provides the enterprise value to EBITDA forward for Immunovant, Inc. (NASDAQ: IMVT) as reported on TradingView. It includes basic company information and financial metrics, indicating that the market was closed at the time of viewing. The content primarily serves as a financial data point for investors interested in IMVT.
Price to sales forward of Immunovant, Inc. – NASDAQ:IMVT
This article focuses on the "Price to sales forward" metric for Immunovant, Inc. (NASDAQ: IMVT). It indicates that the content is a financial data point or analysis provided by TradingView, with data sourced from ICE Data Services and FactSet. The page structure suggests it's part of a larger financial information portal for the company.
Immunovant stock hits 52-week high at 36.39 USD By Investing.com
Immunovant (IMVT) stock reached a new 52-week high of $36.39 and has climbed to $37.20, reflecting a significant 128.44% increase over the past year. Analyst firms like H.C. Wainwright, BofA Securities, and Stifel have reiterated Buy ratings and raised price targets based on compelling Phase 2 rheumatoid arthritis study results and an improved sales outlook for IMVT-1402. Despite this strong performance, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value estimate.
Immunovant (IMVT) CLO mandated share sale to cover RSU tax withholding
Immunovant's Chief Legal Officer, Christopher Van Tuyl, reported an open-market sale of 2,634 shares of common stock at $35.39 per share. This transaction was mandated by the company's "sell to cover" policy to fulfill tax withholding obligations associated with the vesting of previously granted Restricted Stock Units (RSUs), and was not a discretionary trade. Following this sale, Van Tuyl directly holds 180,597 shares of Immunovant common stock.
Immunovant stock hits 52-week high at 36.39 USD
Immunovant Inc. (IMVT) stock reached a new 52-week high at $36.39 and then climbed to $37.20, marking a significant increase of 128.44% over the past year. This surge follows positive analyst updates, with H.C. Wainwright, BofA Securities, and Stifel all raising price targets due to compelling clinical trial results for IMVT-1402 in rheumatoid arthritis and other indications. Roivant Sciences, Immunovant's parent company, also reported a robust cash position, contributing to positive investor sentiment.
Immunovant stock hits 52-week high at 36.39 USD By Investing.com
Immunovant (IMVT) stock reached a new 52-week high, trading at $36.39 and climbing to $37.20, marking a 128.44% increase over the past year. This performance reflects investor confidence despite an InvestingPro analysis suggesting the stock may be overvalued. Recent analyst updates from H.C. Wainwright, BofA Securities, and Stifel have increased price targets based on positive clinical trial results for autoimmune disease therapies and an optimistic outlook for IMVT-1402.
Immunovant Inc (IMVT) Earnings Forecast: Future EPS & Revenue Growth Estimates
Immunovant Inc (IMVT) has a target price of USD 44.00, with analysts forecasting a strong buy trend based on 18 analysts. The company's previous quarter's EPS was USD -0.61, outperforming the market expectation of USD -0.73, and the next quarter's EPS is expected at USD -0.60. Immunovant Inc is currently trading at USD 35.365, reflecting a 1.89% increase.
Immunovant Inc (IMVT) Valuation: PE, PB & Fair Value Analysis
This article provides a brief valuation analysis for Immunovant Inc (IMVT), noting that relevant data for P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. It presents the stock's current price, market capitalization, and daily performance. The page structure suggests that a more comprehensive analysis would typically include these valuation metrics.
Immunovant Inc (IMVT) Institutional Confidence
This article from TradingKey focuses on the institutional confidence in Immunovant Inc (IMVT). It provides the current stock price, market capitalization, and details institutional shareholding data, including changes in shares held by major firms like Roivant Sciences Ltd. and Fidelity Management & Research Company LLC. The data indicates various institutional investors have significant holdings and have adjusted their positions in IMVT.
Immunovant Inc (IMVT) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a detailed risk assessment for Immunovant Inc (IMVT), focusing on its volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Sharpe Ratio, and Return-to-Drawdown Ratio over different periods. The data aims to offer insights into the stock's performance and risk profile for potential investors.
Immunovant Inc (IMVT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Immunovant Inc (IMVT)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and shows no record of stock splits. The page also presents current stock performance data for IMVT.
Immunovant (IMVT) director trades 1,500 shares under 10b5-1 plan
Immunovant director Atul Pande exercised stock options to acquire 1,500 shares at $8.43 per share and simultaneously sold 1,500 shares at $34.02 per share. These transactions were executed on June 15, 2026, under a pre-arranged Rule 10b5-1 trading plan established on December 26, 2025. Following these trades, Pande directly holds 116,731 common stock shares, indirectly holds 20,000 shares through a trust, and retains 69,681 stock options.
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Immunovant (IMVT) stock has gained 12.4% over the past month, driven by encouraging clinical data from its lead candidate, IMVT-1402, which is being developed for multiple autoimmune conditions. The company's strong financial position, with over $900 million in cash, is expected to fund operations through the commercial launch of IMVT-1402 for Graves' disease. Upcoming milestones, including top-line data from significant clinical studies, are further boosting investor confidence.
IMVT (NASDAQ: IMVT) files Form 144 reporting 6,000-share option exercise sale
Immunovant, Inc. (NASDAQ: IMVT) has filed a Form 144 indicating a proposed sale of 6,000 shares related to an exercise of stock options, with a planned sale date of June 15, 2026. The filing also reports a prior 10b5-1 sale of 6,000 shares on May 20, 2026, which generated $192,000. This is a routine regulatory disclosure for insider transactions.
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Immunovant (IMVT) stock has soared 12.4% in the past month due to positive clinical data for its lead candidate, IMVT-1402, which is being developed for multiple autoimmune indications. The company's strong financial position, with over $900 million in cash, is expected to fund operations through the commercial launch of IMVT-1402 for Graves’ Disease. Upcoming data readouts for IMVT-1402 in various indications in 2026 and 2027 are expected to further drive investor confidence.
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Immunovant (IMVT) stock has surged 12.4% in the past month, driven by promising clinical data for its lead candidate IMVT-1402, an expanding autoimmune disease pipeline, and a robust financial position with over $900 million in cash. The company anticipates key data readouts for IMVT-1402 across multiple indications in 2026 and 2027, strengthening investor confidence and extending its cash runway through commercial launch.
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Immunovant (IMVT) stock has risen 12.4% in the past month due to positive clinical data for its lead candidate, IMVT-1402, and a strong financial position with over $900 million in cash. IMVT-1402 is showing promising results in autoimmune indications like difficult-to-treat rheumatoid arthritis, with further data expected in late 2026 and 2027 for other conditions. The company's robust cash balance is projected to fund operations through IMVT-1402's commercial launch for Graves’ disease.
Immunovant Q4 2026 earnings preview
This article is a Q4 2026 earnings preview for Immunovant. No specific financial details or predictions are available in the provided content. The article is extremely short and only provides the topic without further information.
Immunovant Inc stock (US45258Q1058): shares trade around mid-30 USD ahead of next catalysts
Immunovant Inc. shares are trading in the mid-$30 range on Nasdaq as investors focus on its late-stage autoimmune pipeline and upcoming clinical and regulatory milestones. The company, which specializes in FcRn-targeted therapies, is valued based on pipeline probability and cash runway rather than traditional earnings multiples, making clinical progress a key driver for its stock performance.
Behavioral Patterns of IMVT and Institutional Flows
This article analyzes Immunovant Inc. (NASDAQ: IMVT), identifying a weak near-term sentiment that could precede shifts in its mid and long-term outlook. It highlights a significant 41.5:1 risk-reward short setup for the stock and provides three distinct AI-generated institutional trading strategies tailored for different risk profiles and holding periods, including position trading, momentum breakout, and risk hedging strategies.
IMVT Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Immunovant Inc (IMVT), indicating a "Strong Buy" consensus based on various technical indicators. It details momentum indicators like RSI and MACD, support and resistance levels, and different moving averages, all contributing to the strong buy sentiment for the stock. The analysis also answers frequently asked questions regarding IMVT's technical standing.
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
H.C. Wainwright raised its price target for Immunovant (IMVT) to $40 from $35, maintaining a Buy rating after positive Phase 2 rheumatoid arthritis trial data. The firm cited high response rates and the differential action of FcRn treatments compared to JAK/TNF-directed therapies. BofA Securities also boosted its price objective for IMVT to $43 from $32, increasing its peak sales forecast for IMVT-1402 to $6.8 billion.
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45
Major Wall Street analysts have updated their ratings for Immunovant (IMVT.US) on May 22, with price targets ranging from $40 to $45. BofA Securities, Wells Fargo, H.C. Wainwright, and LifeSci Capital maintained buy ratings, adjusting some target prices upwards, while Truist Financial maintained a hold rating. The article provides a summary of these analyst recommendations and their respective target price adjustments for Immunovant.
13 Best Short Squeeze Stocks to Invest In
Immunovant, Inc. (NASDAQ:IMVT) is highlighted as a top short squeeze stock due to positive Phase 2 rheumatoid arthritis trial results, leading to increased price objectives from H.C. Wainwright and BofA Securities. H.C. Wainwright raised its price target to $40 and then to $43, citing high response rates and an upgraded success chance for IMVT-1402. BofA Securities increased its price objective to $43, raising the peak sales forecast for IMVT-1402 to $6.8 billion.
13 Best Short Squeeze Stocks to Invest In
This article identifies Immunovant, Inc. (NASDAQ:IMVT) as one of the best short squeeze stocks, highlighting recent positive analyst revisions following promising Phase 2 rheumatoid arthritis trial results. H.C. Wainwright raised its price target to $40 and BofA Securities increased its target to $43, both maintaining Buy ratings, citing the potential of IMVT-1402. Immunovant develops treatments for autoimmune diseases, focusing on its novel monoclonal antibody IMVT-1402.
Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock
The article reports that Myovant Sciences's Director, Forrester Stephen H., sold 190,000 shares of common stock on May 28, 2026, for a total of $7.44 million. Following this transaction, Forrester Stephen H. still directly owns 75,595 shares in the company.
Immunovant (IMVT) director Fromkin sells 221,951 shares after exercising options
Immunovant director Andrew J. Fromkin exercised stock options for 196,601 shares, then subsequently sold 221,951 shares of common stock in open-market transactions. Following these transactions, Fromkin directly holds 74,382 Immunovant common shares, indicating a net reduction in his direct equity but retaining a meaningful stake. The sales were conducted at weighted average prices of $33.56 and $32.64 per share.
[144] Immunovant, Inc. SEC Filing
Immunovant, Inc. (IMVT) has filed a Form 144 with the SEC, indicating proposed sales of Common shares by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing details multiple proposed sale methods and dates, including the exercise of options under a registered plan, restricted stock vesting, and an open market purchase, with specific lot sizes itemized rather than aggregated. This document is crucial for transparency, allowing investors to understand potential impacts on the stock price.
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
Truist has increased its price target for Immunovant, Inc. (IMVT) from $23 to $30, while keeping a Hold rating. This adjustment follows Immunovant's fiscal year 2026 results and updated model incorporating potential contributions from IMVT-1402 data. The company reported $902.1 million in cash and equivalents, providing substantial runway for development, despite increased R&D expenses driven by clinical trials.
J.P. Morgan Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $47
J.P. Morgan has reiterated its Buy rating for Immunovant (IMVT.US) and increased its price target to $47. This indicates a positive outlook from the investment bank regarding the company's future performance and stock value.
(IMVT) Movement Within Algorithmic Entry Frameworks
This article provides an algorithmic analysis of Immunovant Inc. (NASDAQ: IMVT), identifying strong sentiment across all horizons supporting an overweight bias. It outlines distinct institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for near, mid, and long-term horizons. The analysis highlights key signals, support, and resistance levels generated by AI models.
